Robert Holloway, MD, presents the diagnosis and treatment regimen of a 71-year-old woman with mismatch repair-proficient (pMMR) metastatic endometrial cancer.
Patient started carboplatin/paclitaxel (6 cycles), which was well-tolerated
Patient was scheduled for follow-up visits every 3 months after completion
May 2022(6 months post–chemotherapy completion):
CA-125 level increased to 42.1 U/mL
CT revealed that the previous bladder metastatic mass increased slightly in size
The patient discussed targeted systemic therapy options with her clinician, and she expressed the desire to spend as much time as possible with her grandchildren.
They jointly decided to trial lenvatinib/pembrolizumab, with instructions to continue follow-up visits every 3 months.